Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating

• US 20070293937A1
• Filed: 06/01/2007
• Published: 12/20/2007
• Est. Priority Date: 01/03/2006
• Status: Abandoned Application

• Current Assignee: Cook Incorporated (Cook Group Incorporated), MED Institute, Inc. (Cook Group Incorporated)
• Original Assignee: MED Institute, Inc. (Cook Group Incorporated)
• Inventors: Ragheb, Anthony, Ruane, Patrick, Fearnot, Neal, Grewe, David, Biggs, David
• Application Number:
  US11/809,779
• Publication Number:
  US 20070293937A1
• Time in Patent Office: Days
• US Class Current: 623/1.13
• CPC Class Codes: A61L 2300/434 of enzymes
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

An endoluminal medical device comprises a drug release system that releases a cathepsin inhibitor at a predetermined location within a lumen of a patient. The endoluminal devices and methods of treatment of disease can treat illnesses such as aneurysms and aortic dissections.

Claims

1. An endoluminal medical device including a drug release system operable to release a cathepsin inhibitor at a predetermined location within a lumen of a patient.

2. The device of claim 1, wherein the cathepsin inhibitor is selected from the group consisting of cysteine proteinase inhibitor, aspartic proteinase inhibitors, and serine proteinase inhibitors.

3. The device of claim 1, wherein the cathepsin inhibitor is selected from inhibitors selected from the group consisting of inhibitors of cathepsin B, inhibitors of cathepsin C, inhibitors of cathepsin H, inhibitors of cathepsin L, inhibitors of cathepsin S, inhibitors of cathepsin S, inhibitors of cathepsin K, inhibitors of cathepsin O, inhibitors of cathepsin D, inhibitors of cathepsin E, inhibitors of cathepsin G, and inhibitors of cathepsin A.

4. The device of claim 1, wherein the drug release system comprises a stent.

5. The device of claim 4, wherein the stent is a self-expanding stent or a balloon expandable stent.

6. The device of claim 1, wherein the drug release system comprises a tubular graft material supported by the stent.

7. The device of claim 6, wherein the graft material comprises an extracellular matrix material.

8. The device of claim 1, wherein the device comprises a delivery system for delivering the device and wherein the drug release system is integrated with the delivery system.

9. The device of claim 1, comprising a polymer layer to provide a controlled release of the cathepsin inhibitor at the predetermined location.

10. The device of claim 1, wherein the device is configured for treatment of an aneurysm.

11. The device of claim 10, wherein the aneurysm is an abdominal aortic aneurysm.

12. The device of claim 1, wherein the device is configured for treatment of an aortic dissection.

13. The device of claim 1, wherein a plurality of cathepsin inhibitor compounds are incorporated in multiple coating layers.

14. The device of claim 1, wherein the device is for treating an aneurysm and the drug release system is operable to release cathepsin inhibitor at a location near the aneurysm.

15. The device of claim 14, wherein the aneurysm is an abdominal aortic aneurysm.

16. A method of treating an aneurysm, the method comprising delivering a cathepsin inhibitor releasing device to a location near the aneurysm.

17. The method of claim 16, wherein the device is an endoluminal device comprising a drug release system that releases the cathepsin inhibitor.

18. The method of claim 17, wherein the endoluminal device is a stent graft for treating an aortic aneurysm.

19. The method of claim 16, wherein the cathepsin inhibitor is selected from the group consisting of cysteine proteinase inhibitor, aspartic proteinase inhibitors, and serine proteinase inhibitors.

20. The method of claim 16, wherein the cathepsin inhibitor is selected from inhibitors selected from the group consisting of inhibitors of cathepsin B, inhibitors of cathepsin C, inhibitors of cathepsin H, inhibitors of cathepsin L, inhibitors of cathepsin S, inhibitors of cathepsin S, inhibitors of cathepsin K, inhibitors of cathepsin O, inhibitors of cathepsin D, inhibitors of cathepsin E, inhibitors of cathepsin G, and inhibitors of cathepsin A.

21. A cathepsin inhibitor for use in therapy.

22. The cathepsin inhibitor of claim 21, for use in treating an aneurysm.

23. Use of a cathepsin inhibitor in the manufacture of an endoluminal medical device for treating an aneurysm.